A Nested Case-control Study to Determine the Relative Risk of and Risk Factors for Interstitial Lung Disease in a Cohort of NSCLC Patients Treated With and Without Gefitinib.
Phase of Trial: Phase IV
Latest Information Update: 03 Feb 2018
At a glance
- Drugs Gefitinib (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 17 Dec 2007 Status changed from in progress to completed.
- 08 Jun 2007 Status change from recruting to in progress
- 24 Mar 2006 New trial record.